Table 1.
Baseline demographic and clinical characteristics
| Variable | n (%) | |
|---|---|---|
| Age, years | <70 ≥70 |
24 (44) 30 (56) |
| Sex | Male Female |
42 (78) 12 (22) |
| Etiology | HCV HBV Alcohol-related Unknown |
24 (44) 11 (20) 7 (13) 12 (23) |
| Child-Pugh score, points | 5 ≥6 |
33 (61) 21 (39) |
| TNM staging | III IV |
23 (43) 31 (57) |
| Vascular invasion | - + |
40 (74) 14 (26) |
| Maximum tumor size, mm | <50 ≥50 |
33 (61) 21 (39) |
| Previous therapy | Curative Other None |
35 (65) 14 (26) 5 (9) |
| Serum alpha fetoprotein, ng/mL | <100 ≥100 |
25 (54) 29 (46) |
| DCP, mAU/mL a | <1000 ≥1000 |
27 (52) 25 (48) |
| Initial dose of sorafenib, mg | 200 400 600 800 |
10 (19) 14 (26) 6 (11) 24 (44) |
DCP des-gamma-carboxy prothrombin, HCV hepatitis C virus, HBV hepatitis B virus
aDCP values were not available for two cases